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Abstract
Microfluidic bioartificial organs allow the reproduction of in vivo-like properties such as cell culture in a 3D dynamical micro
environment. In this work, we established a method and a protocol for performing a toxicogenomic analysis of HepG2/C3A
cultivated in a microfluidic biochip. Transcriptomic and proteomic analyses have shown the induction of the NRF2 pathway
and the related drug metabolism pathways when the HepG2/C3A cells were cultivated in the biochip. The induction of
those pathways in the biochip enhanced the metabolism of the N-acetyl-p-aminophenol drug (acetaminophen-APAP) when
compared to Petri cultures. Thus, we observed 50% growth inhibition of cell proliferation at 1 mM in the biochip, which
appeared similar to human plasmatic toxic concentrations reported at 2 mM. The metabolic signature of APAP toxicity in
the biochip showed similar biomarkers as those reported in vivo, such as the calcium homeostasis, lipid metabolism and
reorganization of the cytoskeleton, at the transcriptome and proteome levels (which was not the case in Petri dishes). These
results demonstrate a specific molecular signature for acetaminophen at transcriptomic and proteomic levels closed to
situations found in vivo. Interestingly, a common component of the signature of the APAP molecule was identified in Petri
and biochip cultures via the perturbations of the DNA replication and cell cycle. These findings provide an important insight
into the use of microfluidic biochips as new tools in biomarker research in pharmaceutical drug studies and predictive
toxicity investigations.
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Introduction
In drug development and toxicity studies, there is increased
demand from pharmaceutical companies to develop new ap-
proaches that make it possible to focus on optimum drugs at the
preclinical stage. The use of toxicogenomics (transcriptomics) has
been highlighted to characterize the metabolic consequences of
drug toxicity. Cell response at the transcritpome level has
contributed to identify new biomarkers and to detect the early
symptoms of toxic phenomena in vitro and in vivo [1]. Recent
progress in proteomic analysis has also led to identify biomarkers
at the protein level providing new insights into drug development
and toxicological science [2,3]. The combination of the transcrip-
tomic and proteomic approaches contributes to consistently link
the biochemical pathways involved in toxicity, and thus improving
the descriptions of the toxicological mechanisms of drugs [4].
In order to first clarify and then optimize the therapeutic effects
of molecules, new technology platforms, reproducing the targeted
tissue of the drugs, represent another new research area.
Hepatoxicity is one of the primary causes of late drug withdrawal,
mainly because of the lack of a pertinent model for both
reproducing functional liver tissue and addressing the systemic
toxicity of molecules [5]. Recently, microscale models have been
built to cultivate liver cells in order to refine the investigations with
hepatocytes [6]. The advantages offered by microfabrication
technologies are the design of specific 3D microstructured
environments much more elaborate than classical Petri dish
cultures [7,8]. By controlling the microfluidic flow conditions
inside these environments, the microscale model now makes it
possible to propose successful co-cultures based on various organ
cell types (such as liver, lung etc…), reproducing systemic
interactions [9]. Highly complex and structured liver microscale
models (using human primary hepatocytes and liver non
parenchymal cells) can be successfully applied to pharmaceutical
drug screening [10,11].
An important issue for these microscale cultures is the
development of dedicated platforms representing alternative
methods for in vivo screening. Although there is a desire for
evidence of the model’s performances, there is still a lack of
fundamental biological characterizations and comparisons be-
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microscale models, we developed a microfluidic biochip applied to
mammalian cell cultures [12,13]. In the present investigation, we
aimed to characterize liver cell responses in the microfluidic
biochip using transcriptome and proteome expression profiles. To
confirm the advantages of our microfluidic biochip in toxicological
and pharmaceutical studies, we compared the effect of a well-
known hepatotoxic, the acetaminophen (APAP), on liver cells
cultivated in either Petri dishes or in microfluidic biochip culture
conditions. APAP toxicity is mainly due to its bioactivation by
phase 1 enzyme CYPs into a hypereactive imine: N-acetyl-p-
benzoquinone imine (NAPQI) leading to covalent adducts with
hepatocyte proteins when GSH cellular stock is depleted. Then,
the in vivo literature data were compared in order to analyze
whether or not the combination of the transcriptomic and
proteomic approaches in a microfluidic biochip can improve the
understanding of the biochemical consequences of APAP drug
toxicity.
Results
APAP treatment affects cell morphology, cell cycle
repartition and proliferation in microfluidic biochips
Proliferations of the treated and untreated cells were
compared at the end of culture. At 1 mM, we observed the
proliferation inhibition of 50% in the microfluidic biochip
(Figs. 1A, 1B and Fig. 2A), whereas only 25% of inhibition was
f o u n di nt h eP e t r id i s h e s( F i g s .1 C ,1 Da n dF i g .2 A ) .I na d d i t i o n ,
the treatment led to disrupted cell cycle distribution in both
conditions, resulting in a bloc k a g ei nt h eSp h a s ef o rb o t h
culture systems, as reported in Fig. 2B. In addition, cell
apoptosis analysis using flow cytometry (via annexin V staining)
did not reveal any apoptotic status.
APAP treatment affects cell metabolism in microfluidic
biochips
The metabolic activity was monitored taking albumin secretion
and glucose consumption into account as basal cell markers for the
functionality of the cells (Table 1). APAP treatment influenced the
metabolic activity in both Petri and biochip culture conditions.
Compared to the untreated cultures, glucose consumption was
measured to be 30% higher in Petri dishes and 37% in biochips in
APAP treated conditions. Albumin secretion showed an increase
of 40% in both culture conditions
Interestingly, the APAP conjugation activity differed depending
on the culture conditions (Table 1). We measured a 3-fold higher
secretion of Sulfo-APAP in the biochip when compared to the
Petri cultures. In addition, the Gluthatione-APAP production was
detected only in the biochip. However, we never detected the
Glucurono-conjugation activity, regardless of the culture condi-
tions (Petri or biochip). The production of Glutathione-APAP in
the biochip was correlated with significant CYP1A activity, which
was maintained only in the biochip, as illustrated by EROD
analysis in Table 1.
Microarray analysis and biologically relevant functions in
microfluidic biochips
The filtered gene lists led to extract 1236 differentially
expressed genes between the Petri dishes and the microfluidic
biochip (730 up-regulated and 506 down-regulated by a fold
change classification); 144 genes between the untreated biochip
and the treated biochip (51 down-regulated and 93 up-regulated,
supplement Table S1); and 166 genes between the untreated and
treated Petri dishes (23 down-regulated and 143 up-regulated,
supplement Table S2). The PCA analysis of the global gene
expression in the different conditions is shown in Fig. 3. The first
axis of the analysis discriminated the culture conditions by
Figure 1. Morphology of the HepG2/C3a cells after 96 hours of culture. (A) biochip without APAP; (B) biochip treated with 1 mM of APAP;
(C) Petri dish without APAP; (D) Petri dish treated with 1 mM of APAP.
doi:10.1371/journal.pone.0021268.g001
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second axis of the analysis successfully separated the treated and
untreated cases. The gene lists were introduced in Ingenuity
Pathway Analysis to characterize the biological response of
HepG2/C3a cells in relation to the experimental conditions. The
software provided the ‘‘Top networks’’, the ‘‘Top canonical
pathways’’, ‘‘Molecular and biological functions associated’’ and
‘‘Top tox lists’’ (Table 2).
The comparison between the biochip and Petri (without APAP
treatment) showed that ‘‘drug and lipid metabolisms’’ and
‘‘molecular transport’’ appeared in the ‘‘Top networks’’ signifi-
cantly affected by the microfluidic culture conditions. Since
HepG2/C3a cells are clones derived from a hepatocarcinoma,
‘‘cell compromise’’ and ‘‘cancer pathway’’ were also extracted.
Then, in the ‘‘ToxList’’ we found the RXR/PXR activation
pathway (involved in drug metabolism) and an inflammatory
Figure 2. APAP effect on cell proliferation and cell cycle repartition. (A) Comparison of the cell growth in biochip and Petri dishes in
untreated and treated conditions with 1 mM of APAP after 96 h of cultures (n=6, * P,5%); (B) DNA repartition in biochip and Petri dishes after
96 hours of culture. The DNA repartition show for both culture conditions a disruption of the cell cycle repartition compared to control (n=6*
P,5%).
doi:10.1371/journal.pone.0021268.g002
Table 1. Basal metabolism (glucose consumption and albumin synthesis), APAP conjugation and CYP1A activity in biochip and in
Petri dishes, in treated and untreated cases after 96 h of cultures.
Glucose
consumption
(mg/10
6cell/h)
Albumin
synthesis
(ng/10
6cell/h)
Sulfo-APAP
(pmol/10
6cell/h)
Glucurono-
APAP
Glutathione-
APAP (AU)
CYP1A
(pmol/10
6cell/h)
Biochip control 33688 8 630 Below LOD Below LOD Below LOD 127620
Biochip treated 51612 151649 75612 Bellow LOD 3 201636
Petri control 24639 0 619 Below LOD Below LOD Below LOD Below LOD
Petri treated 34671 5 0 646 1762 Below LOD Below LOD Below LOD
Mean 6SD (n.6); LOD=Limit Of Detection (value equal to 100 ng/ml for the sulfo and glucurono-APAP; 20 ng/ml for the Gluthatione APAP, value equal to 80 nmol/L
in the EROD assay).
doi:10.1371/journal.pone.0021268.t001
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PLoS ONE | www.plosone.org 3 August 2011 | Volume 6 | Issue 8 | e21268Figure 3. Principal Component Analysis. (A) Proteomic analysis; (B) Transcriptomic analysis; (circles denote Petri data, triangles denote biochips
data, black symbols are control data, white symbols are APAP data).
doi:10.1371/journal.pone.0021268.g003
Table 2. Ingenuity analysis of the transcriptomic data related to the biochip effect and to the treatment effect.
Top Networks
Molecular and cellular functions
(p value)
Top canonical pathway
(p value)
Top tox lists
(p value)
Comparison
biochip vs Petri
1/Drug metab., Lipid metab.,
Molecular transport
Lipid Metabolism
(7610
26)
Biosynthesis of steroids
(7610
27)
Cholesterol biosynthesis
(3610
210)
2/ Cellular compromise, Cancer,
Cell morphology
Small Molecule biochemistry
(7610
26)
Fatty acid metabolism
(1610
25)
Fatty acid metabolism (2610
25)
3/ Cell-mediated Immune response
Cellular development, Hematological
System Development and Funct.
Cellular growth and proliferation
(3610
25)
Butanoate metabolism
(3610
24)
LPS/IL1 Mediated inhibition of
RXR Function (3610
23)
4/ Inflammatory response, Gene
expression, Cellular movement
Cellular movement
(1610
24)
Propanoate metabolism
(3610
24)
Oxidative Stress Response
Mediated by Nrf2 (1610
22)
5/Dermatological diseases and
conditions, Inflammatory disease,
Drug metabolism
Glycerolipid metabolism
(5610
24)
PXR/RXR activation (2610
22)
Treatment effect
in biochip
1/ Cellular development, Haemato-
logical system development and
Function, Cellular development
Cell morphology
(2610
24)
D-arginine and D-ornithine
Metabolism (8610
23)
VDR/RXR activation (2610
22)
2/ Gene expression, Cell death,
Cell cycle
Cellular movement
(3610
24)
Sphingolipid metabolism
(1610
22)
CYP450 panel (5610
22)
3/ Cancer, Cell cycle, Gene
expression
DNA replication, recombination
and repair (2610
23)
VDR/RXR activation
(2610
22)
Hormone receptor regulated
cholesterol metabolism (5610
22)
4/Cell-To-Cell Signalling and
Interaction, Immune Cell Trafficking
Cell cycle
(2610
23)
Glycosaminoglycan
degradation (2610
22)
5/Cell Signalling,Embryonic
Development,Tissue Development
Lipid metabolism
(2610
23)
Pyrimidine metabolism
(8610
22)
Treatment effect
in Petri
1/ DNA Replication Recombination
and Repair
Cell cycle (9610
219) Role of BRCA1 in DNA
Damage Response (4610
210)
p53 signalling (4610
28)
2/ Cell Cycle, Cancer, Reproductive
System Disease
DNA replication, recombination
and repair (1610
29)
Role of CHK Proteins in Cell
Cycle Checkpt Ctrl (1610
29)
G2/M transition of the cell cycle
(5610
26)
3/Cell cycle, Cancer Cell Morphology Cellular assembly and organisation
(6610
7)
p53 Signalling (4610
28) G1/S transition of the cell cycle
(4610
24)
4/Cell Death, Cancer, Reproductive
System Disease
Cellular growth and proliferation
(3610
26)
Mitotic Roles of Polo-Like
Kinase (1610
27)
AHR signalling (8610
25)
Cell compromise (1610
25) Pyrimidine Metabolism
(1610
26)
doi:10.1371/journal.pone.0021268.t002
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metabolism (phase 1 and phase 2 enzymes, phase 3 transporters)
were particularly over expressed in the biochip, as shown in
Fig. 4A.
In the biochips, the perturbations triggered by APAP are
presented in Table 2. Among the pathways, ‘‘VDR/RXR
activation’’ appeared to be affected. This pathway is involved in
the hepatic bioconversion of vitamin D and regulation of Ca
2+
homeostasis [14]. ‘‘Cell morphology’’ and lipid metabolism were
also affected when compared to the treated Petri.
In the Petri dishes, different pathways, when compared to the
treated biochips, were specifically highlighted such as ‘‘DNA
damage response’’, ‘‘cell cycle checkpoint control’’, ‘‘p53
signaling’’ and the ‘‘BRCA1 response’’ (Table 2). These pathways
appeared in apoptosis and cell proliferation regulation.
Finally, 36 genes were commonly affected by the treatment
regardless of the culture situations (in Petri dishes or in the
biochip). These commons genes were involved in ‘‘cell cycle’’,
‘‘DNA replication recombination’’ and ‘‘repair functions’’. This
result appeared consistent with the cell cycle repartition analysis
presented in Fig. 2B. ‘‘Pyrimidine metabolism’’ appeared to be
equally affected by the treatment regardless of the culture
situation.
Proteomic analysis and biological relevant functions in
microfluidic biochips
The proteomic analysis highlighted 111 candidate proteins
differentially expressed when we compared the culture conditions
and treatments. The PCA reported in Fig. 3 successfully
distinguished the culture condition between the Petri dishes and
biochip whereas the effect of the treatment was only identified in
the biochip culture conditions.
We found 86 proteins that were differentially expressed between
the Petri dishes and biochip without treatment (40 up-regulated
and 46 down-regulated, supplement Table S3). Of the specific
hepatic markers, we found that the protein expression of albumin
(ALB), aldhedhyde dehydrogenase (ALDH1A1), and GSTO1
were overexpressed (Fig. 4B).
The treatment in the biochip contributed to identify 27
protein spots differentially expressed when compared to the
untreated biochip (17 up-regulated and 10 down-regulated,
supplement Table S4). The proteomic analysis showed that cell
response in the biochip due to the APAP induced a modification
in the cell process related to the ‘‘calcium binding and
homeostasis’’ (via annexin A7 and visinin) and related to lipid
binding, proteolysis and cytosqueleton (via Coronin, Actin,
Keratine, Tubulin). Other specific markers detected in biochips
were involved in cell cycle regulation process (PP2CA, Stratifin),
the apoptosis cascade (Caspase 3, Cathepsin B), glucose
metabolism (G6PD) and pyrimidine metabolism (Thioredoxin
1).
In the Petri dishes, we found only 8 protein spots differentially
expressed resulting from the APAP (6 up-regulated and 2 down-
regulated, supplement Table S5). Although the PCA did not
distinguish the treatment effect in the Petri dishes, the identified
proteins from the Coomassie gel were involved in DNA
replication and the cell cycle regulation process (MCM7, RBBP4,
PCNA and Nucleolin), as well as cytoskeleton organization
(CAP2).
Finally, three identified proteins showed a common alter-
ation between the Petri dishes and biochip conditions because
of the APAP treatment: Annexin A7, Coronin 1B, and the
CK8.
Discussion
Transcriptomic and Proteomic crosslinks in the
microenvironment
The integration of the transcriptomic and proteomic analyses
revealed a significant correlation with the environment effect.
Totally, 26 protein markers detected in the proteomic analysis also
appeared at the gene levels. Ingenuity pathway analysis of the
resulting combination markers for genes and proteins highlighted
the NRF2 pathway and fatty acid metabolism. This NRF2
pathway is related to oxidative stress and xenobiotic response. In
biochip, it led to the over-expression of genes and proteins
involved in glutathione metabolism, protein ubiquitination, phase
1 (CYP P450) and phase 2 (SULT, GST, UGT) enzymes and
phase 3 transporters (ABCC). This stimulated pathway was the
result of the microenvironment and microfluidic culture conditions
without the APAP loading. Despite this cytoprotective response in
the microfluidic biochip, no apoptotic situation was attained.
Stimulation of the ARE (the anti-oxidant responsible element) by
the NRF2 transcription activator resulted in over-expression of
most of the genes found in the transcriptomic analysis including:
VCP, HSP90, STIP1 in the removal and reparation of damaged
proteins; CYPs450, GST, NQO, UGT, SULT, EPHX1, GCLM,
CBR1, and AKR as phase 1 and phase 2 enzymes; SQTSM1,
HO-1, PRDX1, FTL, FTH1, CAT, GPX2, SOD, TXN, and
GSR as antioxidant proteins. In addition, this induction was
clearly confirmed at the proteome level. At the protein level, we
found the over-expression of the specific protein ALDH1A1, FTL
(ferritin), G6PD, GSTO1, HSP90, SULT1A, and they were also
involved in the pathway [15].
Towards predictive toxicity in microfluidic biochips
The NRF2 pathway is an early inflammatory response that
induced the genes involved in the detoxication process and the
response related to oxidative stress. This early stress was attributed
to early cell adaptation to the micro environment [16]. In our case,
NRF2 pathway activation led to a more sensitive response to
APAP treatment when compared to Petri conditions. APAP
overdose is the most common form of drug poisoning in the USA,
resulting in acute liver failure caused by a necrosis of the
hepatocytes in the centrilobular region. The initial offstage in
toxicity was highlighted by Gillette’s works and is defined by the
formation of a hyperactive quinone-imine, NAPQI, via the
bioactivation of APAP by CYPs450. At therapeutic doses (less
than 4 g per day), APAP is conjugated via UDP glucuronotrans-
ferase or sulfotransferase whereas at higher concentrations this
detoxication process is saturated. NAPQI is trapped by Glutathi-
one via the GST enzyme until depletion of the glutathione stock,
leading to covalent binding to the protein [17–19]. Classical
studies demonstrating the hepatotoxic effect of acetaminophen
performed in vitro show that cytotoxicity is observed for a
concentration of APAP ranging up to 5 to 20 mM with
interspecies differences [20]. In our case, acetaminophen led to
an EC50 at a 1 mM concentration for 72 hours of contact only in
the microfluidic biochip configuration. This result is in accordance
with the toxic plasmatic level observed in humans and which
ranges between 1 and 2 mM [21,22]. However, we did not take
into account the protein binding to acetaminophen. Despite
acetaminophen has a weak affinity for plasma proteins (,20%
[23,24]), the protein contents between blood and culture are
different. Thus, the protein binding quantification will be
necessary to fully confirm that the microfluidic biochip condition
is a more ‘‘physiological-like’’ in vivo situation.
APAP Toxicogenomic Analysis in Liver Microchip
PLoS ONE | www.plosone.org 5 August 2011 | Volume 6 | Issue 8 | e21268Figure 4. Mean genes and proteins affected by the culture condition. (A) Mean genes differentially expressed by the environment condition
and involved in hepatic differentiated function; (B) Mean proteins differentially expressed by the environment condition and involved in hepatic
differentiated function.
doi:10.1371/journal.pone.0021268.g004
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could play a critical role in the cell proliferation process [25,26].
Interestingly, this effect results also in a perturbation of the DNA
replication in a CYP independent manner with blockage of the
transition of G0/G1 or S phases. This result also explained why
we found in both biochips and Petri configurations the similar
effect on cell cycle progression in presence or absence of bio
activation of APAP. However, we detected the APAP-GSH
conjugate only in the biochips, illustrating that acetaminophen is
bioactivated into NAPQI in this configuration. This observation
was correlated with the significant CYP1A activity observed in the
biochips. CYP1A is known to bioactivate acetaminophen as
demonstrated in vivo in the double null CYP1A2/CYP2E1 mice
[27] in which mice were protected from APAP toxicity through
the absence of these enzymes. APAP might thus be biotransformed
via the CYP1A in the biochips and produce the hepatotoxic
compound NAPQI. In the biochips, the NAPQI is then trapped
by the glutathione stock and excreted by the cells in its inactive
form as demonstrated by the apparition of Glutathione-APAP.
The depletion of the glutathione cell stock led to covalent binding
of NAPQI to cell components possibly leading to cell perturbation
until cell death. This mechanism may explain the higher cell
growth inhibition observed in the biochips when compared to the
Petri dishes.
Toxicogenomics in the microfluidic biochip highlights
specific and physiological APAP biomarkers
144 genes and 27 proteins were altered when cells were treated
in microfluidic biochips. Among them, only four markers
appeared to be affected at the transcriptomic and proteomic
levels. At the gene level, the hepatic bioconversion of vitamin D
and regulation of Ca
2+ homeostasis [14] (via VDR/RXR with
HES1, HSD17B2, and NCOA1 genes) were affected in the
microfluidic biochip. At the proteome level, we found a down-
regulation of proteins involved in protein synthesis (such as
HNRNPC1/C2, Serine-threonine kinase receptor-associated pro-
tein), and of the proteins involved in the calcium ion binding (such
as Annexin A7, Visinin-like protein 1 and S100P). An increase in
cytosolic calcium concentration is a common death signal resulting
from acetaminophen treatment [28]. This phenomenon was
explained by the arylation (inhibition) of the calcium pump
(Ca
2+-ATPase) by NAPQI, leading to an accumulation of cytosolic
calcium [28–30]. Furthermore, the loss of mitochondria perme-
ability induced by NAPQI binding (the mitochondria being
involved in the Ca
2+ sequestration) also led to an increase in
cytosolic Ca
2+ accumulation [28–30]. This increase was reported
to be enough to activate nucleolar endonucleases and proteases
such as calpain in in vivo mice studies resulting from APAP toxicity
and leading to cell injury [31,32].
Moreover, based on a metabonomic approach, it has been
shown that liver APAP hepatotoxicity induced elevated lipid
concentrations related to lipid metabolism failure in mouse livers
[33]. This APAP hepatoxicity was also correlated with over-
expression of the insulin-like growth factor binding protein-1 gene
(IGFBP-1). Interestingly, we found common results in the biochip
insomuch as at the transcriptional level the APAP induced down-
regulation of lipid metabolism genes (such as GPD1, GPAM,
DAK) and up-regulation of IGFBP-1 (which was not the case in
the Petri dishes). In addition, at the proteome level, we found that
some enzymes involved in lipid production (such as leukotriene A-
4 hydrolase, short-branched chain specific acyl-CoA dehydroge-
nase, and hydroxymethylglutaryl-CoA synthase) were still up-
regulated in the biochip when compared to Petri cultures.
Finally, we also found a decrease in actin, tubulin and coronin-
1b synthesis at the protein levels involved in cytoskeleton
reorganization in the microfluidic biochip. This was correlated
at the gene levels via the modification in the genes group ‘‘Cell
morphology’’ of the ‘‘cell and molecular function’’ category of the
Ingenuity analysis (such as TIMP1, TIMP2, RACGAP1, BTG2,
UCN2, RRAS, KIF14 and CBX5, DNMT3B, LGMN, MCAM,
RRAS). Interestingly, cytoskeleton reorganization has also been
reported in the literature as an in vivo APAP toxicity consequence
[34]. The combination of the genes and proteins affected in the
microfluidic biochip has thus played a part in the identification of
a specific biomarkers signature that appeared closer to the in vivo
one when compared to Petri dishes.
In conclusion, we have analyzed the transcriptomic and
proteomic profiles of HepG2/C3a cultivated in microfluidic
biochips and Petri dishes. The profiles integration have shown
an induction of a cytoprotective response in the biochip leading to
the induction of the cell defense mechanisms. When applied to
acetaminophen toxicity analysis, the microfluidic biochip cultures
have demonstrated a higher physiological response when com-
pared to Petri cultures. In Petri and biochip conditions, the cell
cycle and cellular reorganization were modified by the APAP.
However, the limitation of the HepG2/C3a proliferation was
more important in the biochip leading to reach an IC50 at 1 mM
of APAP (IC25 in Petri respectively). This was attributed to a
probable NAPQI synthesis in biochips due to the induction of the
drug metabolism related genes in the micro environment. Among
the metabolic network affected by the APAP in biochip, we found
the lipid metabolism and the VDR/RXR pathway related to the
calcium homeostasis. Finally, our finding provides a new insight
into the use of microfluidic biochips as new tools in toxicity and
mechanistic researches in pharmaceutical drug studies and
predictive toxicity investigations
Materials and Methods
Microfluidic biochip fabrication
The fabrication details, based on replica molding of poly-
dimethylsiloxane (PDMS) and the choice of microfluidic biochip
design, have been described previously [12,13]. In summary, the
biochip’s construction includes a first PDMS layer with the
microstructures for cell attachment, which contains a series of
microchambers and microchannels inside a larger cell culture
chamber. The biochip has a volume estimated at 40 mL (Fig. 5).
Cell culture conditions
HepG2/C3a was obtained from the American Type Culture
Collection (ATCC, reference CRL 10-741) and cultivated
according the ATCC recommendations. Stock solution of
acetaminophen (APAP) was prepared by direct dilution of powder
(SIGMA) in the medium before dilution at 1 mM. Cell culture
conditions were previously described. Briefly cells were seeded in
biochips and in 12-well culture plates (Becton Dickinson), at the
same density of 0.25610
6 cells/cm
2. Dynamic condition in
biochip was performed after 24 h of adhesion at 10 ml/min. The
APAP was loaded in the biochip circuit and Petri dishes before to
start the perfusion.
In dynamic flow experiments, the biochip were introduced into
a 3 mL circuit loop through the use of a peristaltic pump and a
bubble trap interconnected by silicone tubing with a 1.0 mm
interior diameter. The flow rates were controlled by the pump and
the bubble trap was used as a 2 ml culture medium reservoir. The
cultures were performed simultaneously in non-treated and treated
APAP conditions.
APAP Toxicogenomic Analysis in Liver Microchip
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Cells were trypsinized inside the biochip, collected and washed
with 1 mL of PBS containing 5 mM EDTA. They were then fixed
for 45 min at 4uC in 1 mL of 75% ethanol in PBS with 5 mM
EDTA, washed, suspended in PBS containing 5 mM EDTA,
0.1% Triton X-100 (Promega), 40 mg RNase A (Sigma) and 25 mg
propidium iodide (PI, Sigma), and incubated for 15 min protected
from light. The stained samples were analyzed in an Epics XL-
MCL flow cytometer (Beckman Coulter). The histograms were
analyzed using Wincycle software.
Cell apoptosis was also evaluated by the quantification by
cytometer (Epics XL-MCL flow cytometer (Beckman Coulter) of
the annexin V positive cells. The cells were detached by
trypsinization, washed with PBS and resuspended in binding
buffer (10 mM Hepes/NaOH, pH 7.5 containing 0.14 M NaCl
and 2.5 mM CaCl2). Cell suspension was stained with 0.25 mgo f
annexinV/FITC and 10 mg of Propidium Iodide and analysed.
Metabolism activities
Glucose consumption and albumin production were measured
after 96 h of culture. The protocols have been described in detail
in our previous works [12]. Briefly, the glucose was measured
using a Konelab 20 biochemical analyzer (Thermo Electron
Corporation). Albumin synthesis was measured by means of an
ELISA sandwich technique (anti Human Albumin IgG, Cappel;
anti Human Albumin IgG coupled with peroxydase, Cappel).
CYP1A1/2 activities were determined using 5-ethoxyresorufin
(10 mM) as substrate. Resorufin formation by 7-ethoxyresorufin O-
deethylation (EROD) was quantified with a fluorescence micro-
plate reader (TECAN, Spectrafluor plus) after 1 hour’s incubation
in the presence of salicylamide (3 mM) in order to inhibit phase II
enzymes. Fluorescence was determined at lex 535 nm and lem
595 nm.
APAP metabolites were measured using the LC/MS/MS
method. Medium samples containing APAP were collected at
the end of the culture period. An aliquot of 10 mL of culture
medium was diluted 3 times in A before LC-MS/MS analysis. The
LC-MS/MS system is composed of Dionex Ultimate 3000
capillary HPLC with a Famos injector and a UV UVD 3000
detector. The HPLC chain is coupled with a Triple Quad
WATERS (micromass) Quatro micro mass spectrometer. The
separation process was performed using a Thermo Hypercyl Gold
Aq (15060.5 mm63 mm) colonna. The mobile phase is constitut-
ed with A (Acetate ammonium 10 mM in water) and B
(Acetonitrile 50% and 50% of A) with a flow rate of 8 ml/min.
The gradient of the mobile phases consists of 5% B in A at 0 min
Figure 5. Experimental design description. (A) Perfusion setup and peristaltic pump setup with 6 individual biochips and medium reservoirs; (B)
Microfluidic biochip; (C) Microchannel design inside of the biochip; (D) Experimental procedure.
doi:10.1371/journal.pone.0021268.g005
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of B at 40 min and back to 5% of B at 41 min. The analytes were
detected by MRM (Multiple Reaction Monitoring) in positive ion
mode. The different areas obtained for Glutathione-APAP (MW:
457 g/mol), Glucurono-APAP (MW: 328 g/mol), and Sulfo-
APAP (MW: 232 g/mol) were compared to a known quantity of
each standard (SIGMA) making possible a semi-quantitative
dosage.
RNA extraction, hybridization on Affymetrix chips and
microarray analysis
For the microarray study, the cells were trypsined from the
biochips and Petri dishes in triplicate. Total RNA extraction was
performed after 96 h of culture (Fig. 5). The total RNA was
extracted using a NucleospinH RNA XS isolation kit (Macherey-
Nagel). The quantity of RNA was assessed with a Nanodrop ND-
1000 spectrophotometer (Nyxor Biotech, Paris, France). RNAs
quality was verified with a Bioanalyzer 2100 (Agilent Technolo-
gies, Massy, France). RIN ranged between 9.3 and 10.
The raw data (affymetrix .cel files) were obtained using
affymetrix Genechip operating software. All .cel files were
analyzed using the affymetrix expression console in order to
monitor microarray quality with different control metrics. Data
were normalized using Robust Multichip Average methodology
(RMA) in order to remove handling errors. A PCA (Principal
Component Analysis) was applied to the data using R program.
Mean expression values of the triplicate were calculated and the
gene lists were filtered according to the fold change (on contrary to
our previous work [16]) in order to conserve only the genes with a
fold change of more than 1.8 (up-regulated) or less than 0.55
(down-regulated). Lists of the genes corresponding to the different
experimental conditions were introduced into the ingenuity
pathway to obtain biological functions, top network and gene ID.
Proteomic analysis: 2D Dige
The method follows the instructions of the constructor (Ettan
Dige User manual, GE Healthcare) and the experimental design is
represented in supplement table S6. Briefly, the cells were
collected and the protein concentration determined by a Bradford
method. Then, the proteins were labelled with CyDye DIGE fluor
kit. Labelled samples were mixed in the rehydratation buffer
before to be loaded onto the 18-cm IPG strips (GE-Healthcare)
with equal amount (50 mg). After passive rehydratation, isoelec-
trofocalisation of the different strips was performed using an
IPGphor apparatus (GE Healthcare) for a total of 70 kV.h. At the
end of the cycle, strips were stocked at 220uC before equilibration
step. Equilibrated strips were placed onto homemade polyacryl-
amide gels (8–18%), overlaid with agarose solution and electro-
phoresis was performed simultaneously in a Ettan-DALT II system
(GE Healthcare) at 2.5 W/gel at 15uC until the bromophenol blue
dye reached the bottom of the gels. Gels were scanned using a
Typhoon 9400 (GE Healthcare) with a resolution set at 100 mm.
Image analysis were performed by Decyder software suite (GE
Healthcare, version 5.02) which allow the comparison of the
different combination corresponding to the experimental condi-
tions. Down or up-expressed proteins of the different experimental
conditions (microfluidic biochip, petri dishes) were retained if
protein spot fold change was larger than +1.5 or smaller than 21.5
and a Student’s t-test p-value less than 0.05. PCA (Principal
Component Analysis) was performed on the global proteins
distribution to see the different repartition according the
experimental conditions. Spots of interest were manually excised
on Coommassie Blue gel by visual comparison with 2D-Dige
master gel. For MS and MS/MS analysis, the sample analysis was
performed using a MALDI-TOF-TOF 4800 mass spectrometer
(Applied Biosystems). Spectra acquisition and processing was
performed using the 4000 series explorer software (ABI) version
3.5.28193 in positive reflectron mode at fixed laser fluency with
low mass gate and delayed extraction. Database searching was
carried out using Mascot version 2.2 (MatrixScience, London,
UK) via GPS explorer software (ABI) version 3.6 combining MS
and MS/MS interrogations on Human proteins from Swissprot
databank, 18138 entries, (Swissprot databank: 333445 sequences;
120048673 residues, www.expasy.org). The search parameters
were as follows: carbamidomethylation as a variable modification
for cysteins and oxidation as a variable modification for
methionines. Up to 1 missed tryptic cleavage was permitted and
mass accuracy tolerance of 30 ppm for precursors and 0.3 Da for
fragments were used for all tryptic mass searches. Positive
identification was based on a Mascot score above the significance
level (i.e. ,5%). The reported proteins were always those with the
highest number of peptide matches. Under our identification
criteria, no result was found to match to multiple members of a
protein family.
Supporting Information
Table S1 Differentially expressed genes by the APAP treatment
in biochip when compared to the untreated biochip (fold change
above 1.8 or below 0.55).
(DOC)
Table S2 Differentially expressed genes by the APAP treatment
in Petri when compared to the untreated Petri (fold change above
1.8).
(DOC)
Table S3 Proteins differentially expressed by the biochip versus
the Petri and successfully identified by MS/MS.
(DOC)
Table S4 Differentially expressed proteins by the treatment
effect in biochip and successfully identified by MS/MS.
(DOC)
Table S5 Differentially expressed proteins by the treatment
effect in Petri dishes and successfully identified by MS/MS.
(DOC)
Table S6 Experimental design and samples labelling of the
proteomic analysis. Each biochip and Petri is the pool of three
independent replicates.
(DOC)
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